Business Standard

Friday, December 27, 2024 | 05:25 PM ISTEN Hindi

Notification Icon
userprofile IconSearch

Indoco Remedies zooms 20% as Goa plant clears USFDA inspection

The stock is locked in upper circuit of 20% at Rs 206 on the BSE after the US health regulator cleared inspection of the company's Goa plant II & III with two minor observations.

Photo: iStock
Premium

Photo: iStock

SI Reporter Mumbai
Shares of Indoco Remedies are locked in upper circuit of 20% at Rs 206 on the BSE after the US health regulator cleared inspection of the company’s Goa plant II & III with two minor observations.

“The US Food and Drug Administration (USFDA) inspected the company’s sterile facility (plant II) and solid dosages facility (Plant III) situated at Goa from 14th November till 21st November 2018. The inspection concluded with the company receiving 2 minor observations, none of which are repeat in nature,” Indoco Remedies said in a press release.

This facility had received a warning letter from

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in